VRTXVertex

Pharma & Healthcare · US · Vertex Pharmaceuticals Incorporated

4 of 6 ratios computed · receipts verified server-side

Idiot Index

out of 100 · 4/6 ratios · FY 2023

The full receipt

Latest published value for each ratio, with the sector median for context and year-over-year change where the prior year is available.

Markup →
How much revenue per dollar of cost.
8.3769× revenue / costverified
$1 of cost becomes $8.38 of revenue
Sector median: 3.1882Top 11% for extraction in sector
FY 2023v1.0.0
Operational Markup →
Revenue per dollar of cost + operating expenses. The multiplier after legitimate operations.
1.5805× revenue / (cost + opex)verified
$1 of cost+opex becomes $1.58 of revenue
Sector median: 1.2871Top 9% for extraction in sector
FY 2023v1.0.0
Labor Share →
How much of every revenue dollar reaches workers.
Not computed: missing input.
Needed but not in this company's XBRL filings: Total Employee Compensation.
What this company did disclose: Stock Buybacks, Cost of Goods Sold, Total Employee Count, Net Income, Operating Expenses, R&D Expense, Revenue
Executive Extraction →
How many times a CEO out-earns the median employee.
Not computed: missing inputs.
Needed but not in this company's XBRL filings: CEO Total Compensation, Median Employee Compensation.
What this company did disclose: Stock Buybacks, Cost of Goods Sold, Total Employee Count, Net Income, Operating Expenses, R&D Expense, Revenue
Shareholder Extraction →
Dollars sent to shareholders for every dollar invested in R&D.
0.7356× buybacks+dividends / R&Dverified
$0.74 to shareholders per $1 in R&D — net reinvesting
Sector median: 0.7492Median range for extraction in sector
FY 2023v1.0.0
Capital Extraction →
How much of net profit goes to shareholders rather than back into the business.
0.6086× buybacks+dividends / net incomeverified
61% of net profit returned to shareholders, 39% reinvested
Sector median: 0.5294Median range for extraction in sector
FY 2023v1.0.0